The effects of clinically relevant reference agents in a mouse model of severe asthma

Alan Young (nottingham, United Kingdom), Puneeta Nath, Emma Sadler, Vince Russell, Alan Young

Source: International Congress 2015 – Advances in the future treatment of severe asthma
Session: Advances in the future treatment of severe asthma
Session type: Oral Presentation
Number: 1776
Disease area: Airway diseases

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Alan Young (nottingham, United Kingdom), Puneeta Nath, Emma Sadler, Vince Russell, Alan Young. The effects of clinically relevant reference agents in a mouse model of severe asthma. Eur Respir J 2015; 46: Suppl. 59, 1776

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of different PV extracts in the treatment of asthma in an animal model
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015

A murine ovalbumin model exhibits molecular features of steroid insensitive human asthma
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015

An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013

The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013

The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Characterisation of a steroid-insensitive severe asthma model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

The effect of anti-IL-33 antibody and soluble ST2 in a murine model of allergic asthma
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013

Standardization of a murine model of asthma due to soybean inhalation
Source: International Congress 2015 – Occupational and environmental effects: in vitro and animal models
Year: 2015

Adipose derived stem cells ameliorate airway inflammation in mouse models of asthma
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015


The effect of lipopolysaccharide-contaminated ovalbumin on airway inflammation and remodeling in a chronic murine asthma model
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013


LATE-BREAKING ABSTRACT: MUC1 downregulation induces corticosteroid resistance in asthma’s in vitro and in vivo models
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016

Immunomodulatory role of IL-37 in asthma pathogenesis
Source: International Congress 2016 – Immune responses in the lung
Year: 2016

Mapping a mouse model of severe asthma to human asthma using gene set variation analysis
Source: International Congress 2015 – Advances in the future treatment of severe asthma
Year: 2015

Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016

Developing a chronic murine model that better reflects the clinical features of the human asthma
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016

IL33 and TSLP involvements in influenza-induced exacerbation in a murine model of chronic asthma
Source: International Congress 2015 – Advances in asthma and allergy in animal models
Year: 2015

Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


PI3Kδ inhibition confer efficacy in experimental models of allergic airway inflammation
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015


Investigating antioxidant therapy for steroid-resistant asthma
Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Year: 2016

Crucial timing of a viral component exposure to exacerbate allergen-induced asthma
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016